{"id":17,"date":"2024-12-01T12:08:29","date_gmt":"2024-12-01T12:08:29","guid":{"rendered":"https:\/\/www.naccf.org.np\/?page_id=17"},"modified":"2024-12-09T11:45:10","modified_gmt":"2024-12-09T11:45:10","slug":"events","status":"publish","type":"page","link":"https:\/\/www.naccf.org.np\/?page_id=17","title":{"rendered":"Events"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;11px||0px|||&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Introduction of the HPV Vaccine in Nepal &#8211; 2008 &#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;center&#8221; title_text_color=&#8221;#423947&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; text_line_height=&#8221;1.8em&#8221; background_color=&#8221;#EBF4F6&#8243; custom_padding=&#8221;15px|11px|15px|11px|true|true&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<h2>HPV Vaccination \u2013 Gardasil<\/h2>\n<p>(Gardasil is\u00a0 quadrivalent vaccine that protects against four strains of HPV HPV 16 &amp;18 \u2013 causing approx 75% of cervical cancer cases HPV 6 &amp; 11 \u2013 causing approx 90% of genital warts Gardasil can also protect against vaginal and vulvar cancer. Gardasil does not protect against cervical cancer and diseases caused by other HPV strains.\u00a0 Therefore, even with the use of the vaccine, routine screening is essential )<\/p>\n<p><strong>Gardasil information <\/strong><\/p>\n<p><strong>\u00a0<\/strong>(The Gardasil vaccine is most effective when administered between ages 9 to 26 years.\u00a0Vaccine administered intramuscularly into upper arm. Three doses are required for vaccine to be effective.\u00a0 1st dose,\u00a0 2nd dose given 2 months after 1st dose, 3rd dose given 4 months after the 2nd Side effects are uncommon but include pain, swelling, itching, bruising and redness at the injection site.\u00a0 Headache, fever, nausea, dizziness, vomiting and fainting have also been observed)<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;2_3,1_3&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;2_3&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; text_line_height=&#8221;1.8em&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2>HPV Vaccine school-based program\u00a0 2008-2014<\/h2>\n<p><strong><\/strong><\/p>\n<p>The Gardasil HPV vaccine was introduced in Nepal in 2008 and\u00a0 implemented by the Nepal Australian Cervical Cancer Foundation (NACCF) and supported by the AXIOS Gardasil Access Program (GAP) USA, Australian Cervical Cancer Foundation (ACCF), Australian Himalayan Foundation (AHF)<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/www.naccf.org.np\/wp-content\/uploads\/2024\/12\/hpv2.jpg&#8221; title_text=&#8221;hpv2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_2,1_2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; text_line_height=&#8221;1.8em&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>Program Design<\/strong><\/p>\n<p><strong><\/strong><\/p>\n<ul>\n<li>Family Health Division (FHD) communicates official program information to the district level government agencies to encourage support<\/li>\n<li>Contact made with the public, community, private schools and their associations to reach girls, parents\/guardians<\/li>\n<li>Community meetings set up as an interactive environment for school administrators to provide information and teach girls and their parents about the vaccine<\/li>\n<li>Girls asked to bring back signed consent forms to school prior to the day of first vaccination.<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; text_line_height=&#8221;1.8em&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>Administration Sites <\/strong><\/p>\n<p>Schools were selected as the key administration site for several reasons:<\/p>\n<p>1. Maximum numbers of girls are accessible through schools<\/p>\n<p>2. Schools provide a convenient way to run vaccine awareness programs for students, teachers and\u00a0\u00a0\u00a0 parents with easy follow-up<\/p>\n<p>3. Schools provide better chance for higher compliance<\/p>\n<p>4. A coordinator for the vaccine project was nominated by the school administration in each school<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; text_line_height=&#8221;1.8em&#8221; custom_padding=&#8221;11px||||false|false&#8221; hover_enabled=&#8221;0&#8243; border_width_top=&#8221;1px&#8221; border_width_bottom=&#8221;1px&#8221; global_colors_info=&#8221;{}&#8221; border_color_all=&#8221;#37B7C3&#8243; sticky_enabled=&#8221;0&#8243;]<\/p>\n<p><strong>Acknowledgments<br \/>Partners <\/strong><\/p>\n<ul>\n<li>Government Involvement<\/li>\n<li>Vaccine program approval was granted by the Ministry of Health and Population (MoHP)<\/li>\n<li>Monitoring of district level program implementation was done by Family Health Division (FHD)<\/li>\n<\/ul>\n<p><strong>Local Partners<\/strong><\/p>\n<ul>\n<li>Government District Health Offices (DHO):<\/li>\n<li>DHO Makwanpur district<\/li>\n<li>DHO Kapilbastu District<\/li>\n<li>BPKM Cancer Hospital (Government Cancer Hospital) Chitwan<\/li>\n<li>Private Pharmaceuticle Co. (Yetichem) at Kathmandu to provide main cold chain management needs at no cost<\/li>\n<li>Other district level Government agencies and<\/li>\n<li>NGOs at Kaski, Kathmandu, Bhaktapur , Lalitpur , Kavre , RRPC Sarlashi, RYC , Mohottari, REED Nepal ,Solukhumbu<\/li>\n<li><\/li>\n<\/ul>\n<p><strong>International Partners <\/strong><\/p>\n<ul>\n<li>Australian Cervical Cancer Foundation (ACCF) Brisbane provided financial and institutional support for local management<\/li>\n<\/ul>\n<p>Axios-managed Gardasil Access Program provided Gardasil through a pledge from Merck and Co.<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; specialty=&#8221;on&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;-89px|||||&#8221; custom_padding=&#8221;126px||0px|||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_2&#8243; specialty_columns=&#8221;2&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_row_inner _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column_inner saved_specialty_column_type=&#8221;1_2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; text_line_height=&#8221;1.8em&#8221; background_color=&#8221;#EBF4F6&#8243; custom_padding=&#8221;16px|20px|4px|20px|false|true&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<p><strong>HPV Vaccine program implementation <\/strong><\/p>\n<p>Total Vaccinated girls : 30,560<\/p>\n<p>Target group : 11 to 13 age group<\/p>\n<p>Vaccinated District : Kavre, Kathmandu, Lalitpur, Bhaktapur, Makawanpur, Chitawan, Kaski, Kapilbastu, Sarlahi, Mahottari, Solukhumbu<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p>[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column_inner saved_specialty_column_type=&#8221;1_2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; text_line_height=&#8221;1.8em&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>Program Successes<\/strong><\/p>\n<p>Prior to the introduction of HPV Vaccine in Nepal in 2008, knowledge of vaccine was extremely limited.\u00a0 Now, awareness has risen dramatically across Nepal.\u00a0\u00a0 Safely delivered vaccination to 30,560 girls in the target group of 11-13 years of age. No record of life threatening AEFI for recipients.\u00a0 Gardasil vaccine now available on the Nepali drug-store market. Information material has been developed in Nepali. Had success (although still a challenge) in overcoming bureaucratic, social and cultural barriers.<\/p>\n<p>[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column_inner saved_specialty_column_type=&#8221;1_2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; text_line_height=&#8221;1.8em&#8221; background_color=&#8221;#EBF4F6&#8243; custom_padding=&#8221;16px|20px|4px|20px|false|true&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<p><strong>Overcoming Challenges \u2013 what is needed&#8230;<\/strong><\/p>\n<ol>\n<li>Active cooperation from school administrations, to encourage compliance as well as increased awareness and education through local and national media in the hope of minimizing skepticism amongst the community, school girls and their parents.<\/li>\n<li>The World Health Organization to more actively provide publicity to clear misinformation on vaccine projects as &#8216;new&#8217; or &#8216;experimental&#8217;.<\/li>\n<\/ol>\n<ul><\/ul>\n<p><strong>\u00a0<\/strong><\/p>\n<p>[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][\/et_pb_column][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; text_line_height=&#8221;1.8em&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>\u00a0<\/strong><strong>Lessons Learned\u00a0 &amp; Challenges<\/strong><\/p>\n<p>The awareness of HPV and\/or cervical cancer morbidity and mortality is still very low in urban areas and almost zero in rural areas.\u00a0 Very little knowledge of HPV vaccine or other vaccines.\u00a0 Focus amongst Nepalese people still on treatment of immediate health problems rather than prevention. Benefit is not seen until years after immunization<\/p>\n<p>Concern on HPV vaccination as a \u2018new\u2019 or &#8216;experimental&#8217; program.<\/p>\n<p>School administrations are often hesitant to run vaccine program due to:<\/p>\n<ol>\n<li>Concerns about any adverse reactions that may arise and who will be responsible<\/li>\n<li>Limited knowledge of the HPV vaccine, including benefits and safety profile<\/li>\n<li>Concerns over not having enough time to conduct the program<\/li>\n<\/ol>\n<p>Follow-up for 2nd and 3rd doses became challenging without active cooperation of the school administration<\/p>\n<p>For that reason, schools were encouraged to keep detailed follow-up information in a computerized database at NNCTR in Banepa following each vaccination round<\/p>\n<p>\u2013 The cost of the vaccine is sometimes a barrier<\/p>\n<p>\u2013 The Government\u2019s position regarding the vaccine is not clear<\/p>\n<p>\u2013 There are inadequate resources<\/p>\n<p>\u2013 Ensuring the maintenance of vaccine quality under cold chain methods<\/p>\n<p>\u2013 There are challenges associated with full compliance and timing<\/p>\n<p>\u2013 The percentage of drop outs in the 2nd and 3rd\u00a0 doses can be high for\u00a0many reasons such as absentees, illness and others.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;13px|||||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; text_line_height=&#8221;1.8em&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>Conclusion<\/strong><\/p>\n<ol>\n<li>30,560school girls of 11 to 13 age group have vaccinated through the NACCF vaccination program.<\/li>\n<li>A comprehensive Cervical Cancer Prevention Program inclusive of Cervical cancer education, Cervical Cancer Screening and HPV Vaccination is the need of the day in women health services of the country.<\/li>\n<\/ol>\n<p>The HPV vaccination and screening programs run by the NACCF\/NNCTR only touch the tip of the iceberg.\u00a0 There are many, many girls who have yet to be vaccinated.\u00a0\u00a0 <\/p>\n<p>[\/et_pb_text][et_pb_image src=&#8221;https:\/\/www.naccf.org.np\/wp-content\/uploads\/2024\/12\/T1.png&#8221; title_text=&#8221;T1&#8243; align=&#8221;center&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_image src=&#8221;https:\/\/www.naccf.org.np\/wp-content\/uploads\/2024\/12\/T2.png&#8221; title_text=&#8221;T2&#8243; align=&#8221;center&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>HPV Vaccination \u2013 Gardasil (Gardasil is\u00a0 quadrivalent vaccine that protects against four strains of HPV HPV 16 &amp;18 \u2013 causing approx 75% of cervical cancer cases HPV 6 &amp; 11 \u2013 causing approx 90% of genital warts Gardasil can also protect against vaginal and vulvar cancer. Gardasil does not protect against cervical cancer and diseases [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-17","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.naccf.org.np\/index.php?rest_route=\/wp\/v2\/pages\/17","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.naccf.org.np\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.naccf.org.np\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.naccf.org.np\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.naccf.org.np\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=17"}],"version-history":[{"count":12,"href":"https:\/\/www.naccf.org.np\/index.php?rest_route=\/wp\/v2\/pages\/17\/revisions"}],"predecessor-version":[{"id":494,"href":"https:\/\/www.naccf.org.np\/index.php?rest_route=\/wp\/v2\/pages\/17\/revisions\/494"}],"wp:attachment":[{"href":"https:\/\/www.naccf.org.np\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=17"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}